Jasper Therapeutics, Inc. current report, 22 December 2020

Full document

SEC Form 8-K Summary

Registrant: Amplitude Healthcare Acquisition Corporation, a special purpose acquisition company; the request metadata identifies Jasper Therapeutics, Inc., but Jasper is not named as the registrant in the filing.

Reporting date: December 22, 2020. The report was filed under Item 5.07, Submission of Matters to a Vote of Security Holders.

Business Context and Reporting Period

The Company held its 2020 annual meeting of stockholders on December 22, 2020. Stockholders voted on the election of two Class I directors and ratification of the independent registered public accounting firm for the year ending December 31, 2020.

Financial and Operating Metrics

  • The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other operating performance metrics.
  • The Company’s securities traded on Nasdaq under symbols AMHCU, AMHC, and AMHCW.

Voting Results and Material Changes

  • Director elections: Peter Dolan and Glenn Reicin were each re-elected as Class I directors to serve until the 2023 annual meeting or until their successors are elected and qualified.
  • Each director received 2,500,000 votes for, zero votes against, and zero abstentions; broker non-votes were not applicable.
  • Independent auditor: Stockholders ratified the selection of WithumSmith+Brown, PC as the independent registered public accounting firm for the year ending December 31, 2020.
  • The auditor proposal received 9,132,167 votes for, zero votes against, and 151 abstentions; broker non-votes were not applicable.

Guidance, Outlook, Risks, and Unusual Items

The filing contains no financial guidance, operating outlook, management commentary, contingencies, or unusual items. It reports only governance matters and the auditor ratification.

Investor Verification Points

  • Confirm the correct entity: the filing is for Amplitude Healthcare Acquisition Corporation, not Jasper Therapeutics, Inc.
  • Verify the director election results and terms for Peter Dolan and Glenn Reicin.
  • Verify WithumSmith+Brown, PC’s appointment for the year ending December 31, 2020.
  • Review separate filings for the Company’s financial condition, acquisition activity, liquidity, and any transaction involving Jasper Therapeutics.